drugset / Trial / NCT05950724

RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

NCT05950724

Phase 0 Enrolling by invitation 20 enrolled Northwestern University
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.

Timeline

Start
2023-09-17
Primary completion
2026-12
Completion
2027-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg Subcutaneous

Indications

No indication recorded.